ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has announced three senior appointments to its newly incorporated subsidiary company, Inaphaea BioLabs (Inaphaea).
Headquartered in MediCity Nottingham, Inaphaea will offer a wide range of pre-clinical and drug discovery testing services to academic, biotech and pharmaceutical researchers, forming the foundation of ValiRx’s tCRO™ (translational Contract Research Organisation) strategy.
AMSBIO has published an interview with Professor Ryuji Morizane, a renowned expert in renal research at Harvard Medical School. In his award-winning research*, Professor Morizane has successfully combined organoid and bioengineering technology to create kidney organoids that incorporate a vascular structure.
CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System
Check out your monthly round up of employee engagement opportunities in this month's People Pathways newsletter!
ICRISAT and Eagle Genomics sign Memorandum of Understanding
NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
Stevenage, UK, 22 February 2023 - NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a second $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to support its lead drug discovery programme and the development of a novel treatment for Parkinson’s.
In October 2022, the EDPB launched a public consultation on the targeted update of paragraph 73 of the 9/2022 Guidelines on personal data breach notification under the GDPR. Similar to the principles set out in the Working Party 250 Guidelines on personal data breach notification under Regulation 2016/679 (revised in 2018), the EDPB only introduced a major update to data breach notification rules applicable to non-EU companies subject to GDPR.
Click here to view the February 2023 edition of The Meeting Place
We are launching a new study into Equality, Diversity & Inclusion (ED&I) practices within the UK Life Sciences sector. This important research will help to inform our thinking as we develop and implement an ED&I strategy for the sector that promotes best practices.
We want to invite you to take a short survey to help provide an evidence base for the upcoming report. - https://www.surveymonkey.co.uk/r/Z72D2JS
The survey closes on 24 February 2023 and takes approximately just 7 minutes to complete.